Abbott cuts sales reps amid "shifting resources"

Share this article:

Abbott laid off approximately 175 sales reps in the US, Dow Jones reported yesterday.

The company "shifted resources" within its US pharma business, and layoffs were not related to a specific brand, Scott Stoffel, an Abbott spokesperson, told MM&M. "[The layoffs] were largely due to some shifts made in geographical territories," said Stoffel, referring to sales rep assignment areas.

The layoffs follow the completion of Abbott's $6.2 billion acquisition of Solvay Pharmaceuticals in February. Abbott expects the Solvay deal to bring in an additional $2.9 billion in 2010 global sales, the company said in a February statement. Stoffel told Dow Jones that there were no plans for any additional sales force cuts.

Abbott announced on Tuesday that Certriad, a combination of AstraZeneca's Crestor and Abbott's Trilipix, received a complete response letter from the FDA, asking that the company provide additional information on the as yet unapproved cholesterol drug.

Separately, Abbott announced the submission of a new diagnostic test for FDA review. The test, if approved, would help identify patients at risk for acute kidney injury, and would represent the first test available in the US for the detection of neutrophil gelatinase-associated lipocalin.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.